New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 27, 2013
11:55 EDTRHHBY, HALOHalozyme volatility at 16-month low after receiving milestone payment from Roche
Halozyme (HALO) overall option implied volatility of 70 is below its 26-week average of 88 according to Track Data, suggesting decreasing a day after receiving a $10M milestone payment from Roche (RHHBY).
News For HALO;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
07:51 EDTRHHBYRoche catching up fast to Bristol-Myers in immuno-oncology, says Jefferies
Subscribe for More Information
August 24, 2015
12:01 EDTRHHBYRoche buys nucleic acid purification technology from Lumora
Roche has signed a definitive asset purchase agreement with Lumora for products associated with the patent-protected Heat Elution technology for nucleic acid purification of multiple sample types including challenging formalin-fixed paraffin-embedded tumor samples. Roche plans to explore integrating this technology into its sequencing workflow solution.
08:31 EDTHALOHalozyme names Michael LaBarre chief scientific officer
Halozyme named Michael J. LaBarre, Ph.D. as chief scientific officer, succeeding Dr. Michael Shepard, who was appointed a Research Fellow for the company. "Mike has deep experience characterizing early stage assets, making him an ideal leader for our research organization as we invest further in our promising pipeline," said Dr. Helen Torley, president and chief executive officer. "We have a full agenda for the second half of 2015 as we broaden the study of our investigational new drug PEGPH20 in multiple tumor types and prepare for our pivotal phase 3 study in pancreatic cancer patients. I am pleased to have a proven leader of Mike's caliber to guide our research efforts as we invest for future growth."
August 23, 2015
12:35 EDTRHHBYBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
09:38 EDTRHHBYUBS global healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
August 17, 2015
05:14 EDTRHHBYGenentech reports atezolizumab pivotal Phase II study met primary endpoint
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use